Creatine monohydrate in myotonic dystrophyA double-blind, placebo-controlled clinical study
详细信息 查看全文
- 作者：Maggie C. Walter ; Peter Reilich ; Hanns Lochm¨¹ller ; Ralph Kohnen ; Beate Schlotter ; Hubert Hautmann ; Elmar Dunkl ; Dieter Pongratz and Wolfgang M¨¹ller-Felber
- 关键词：Key words myotonic dystrophy (MD) ; creatine monohydrate ; therapy ; supplementation
- 刊名：Journal of Neurology
- 出版年：2002
- 出版时间：December 2002
- 年：2002
- 卷：249
- 期：12
- 页码：1717-1722
- 全文大小：367 KB
文摘
We assessed safety and efficacy of creatine monohydrate (Cr) in myotonic dystrophy (DM1) in a double-blind, cross-over trial. Thirty-four patients with defined DM1 were randomized to receive Cr and placebo for eight weeks (10.6 g day 1–10, 5.3 g day 11–56) in one of 2 treatment sequences. There was no significant improvement using manual and quantitative muscle strength, daily-life activities, and patients' own global assessment comparing verum with placebo administration. Cr supplementation was well tolerated without clinically relevant side effects, but did not result in significant improvement of muscle strength or daily-life activities.